Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Martin Loos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1612-7017; OpenAlex author ID A5114118982. Sources: OpenAlex.

Their work

Papers
37 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
147
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 4 papers · 2024: 8 papers · 2025: 7 papers · 2026: 12 papers

Papers 37

  1. [S3 guidelines on exocrine pancreatic cancer 2024 : Consequences for the surgical practice]. First author DOI 10.1007/s00104-026-02561-7↗
  2. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  3. Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2026.04.007↗
  4. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  5. Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006407↗
  6. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Last author DOI 10.1097/sla.0000000000006532↗
  7. Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study. Co-author DOI 10.1245/s10434-025-18698-4↗
  8. ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after Pancreatic Cancer Resection: A Retrospec… Co-author DOI 10.1245/s10434-025-18864-8↗
  9. Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-026-19264-2↗
  10. ASO Author Reflections: What is the Role of Time Interval Between Preoperative Chemotherapy and Surgery in Locally Advanced Pancreatic Cancer? First author DOI 10.1245/s10434-026-19507-2↗
  11. Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation? Co-author DOI 10.21037/hbsn-2025-587↗
  12. Preoperative biliary stenting is associated with functional dysbiosis and impaired bile acid metabolism in pancreatic cancer - Impact of preoperative biliary s… Co-author DOI 10.64898/2026.05.19.719953↗
  13. ChatGPT vs. surgeons on pancreatic cancer queries: accuracy & empathy evaluated by patients and experts. Co-author DOI 10.1016/j.hpb.2024.11.012↗
  14. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  15. Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study protocol for the multicentre randomized cli… Co-author DOI 10.1093/bjsopen/zraf169↗
  16. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  17. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000006687↗
  18. Challenges and adaptations in pancreatic cancer surgery during the COVID-19 pandemic in a high-volume center. Last author DOI 10.1186/s12885-025-13512-6↗
  19. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  20. [Sex differences in pancreatic cancer]. Co-author DOI 10.1007/s00104-024-02150-6↗
  21. The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding. Co-author DOI 10.1007/s00423-024-03355-3↗
  22. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  23. Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery. Co-author DOI 10.1038/s41598-024-70441-3↗
  24. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  25. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538↗
  26. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  27. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  28. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  29. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  30. Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival. Co-author DOI 10.1097/sla.0000000000005444↗
  31. Distal Pancreatectomy With En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer: A Safe and Effective Procedure. Co-author DOI 10.1097/sla.0000000000005866↗
  32. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve. Co-author DOI 10.1097/sla.0000000000004054↗
  33. Radiological evaluation of pancreatic cancer: What is the significance of arterial encasement >180° after neoadjuvant treatment? Last author DOI 10.1016/j.ejrad.2021.109603↗
  34. Periarterial divestment in pancreatic cancer surgery. Co-author DOI 10.1016/j.surg.2020.08.030↗
  35. Response to the Comment on "Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve". Co-author DOI 10.1097/sla.0000000000004788↗
  36. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  37. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. First author DOI 10.1002/cncr.26344↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 16 shared papers, 2021–2026 · strength 3.15
  2. Markus Wolfgang Büchler · 17 shared papers, 2012–2026 · strength 3.09
  3. Thomas P. Hank · 11 shared papers, 2025–2026 · strength 2.95
  4. Ingmar Florin Rompen · 10 shared papers, 2024–2026 · strength 2.07
  5. Mohammed Al‐Saeedi · 8 shared papers, 2023–2026 · strength 1.99
  6. Christoph W. Michalski · 9 shared papers, 2024–2026 · strength 1.96
  7. Benedict Kinny‐Köster · 9 shared papers, 2023–2026 · strength 1.65
  8. Marc G. Besselink · 8 shared papers, 2024–2026 · strength 1.40
  9. Ammar A. Javed · 8 shared papers, 2024–2026 · strength 1.40
  10. Oliver Strobel · 7 shared papers, 2021–2026 · strength 1.35
  11. Lois A. Daamen · 7 shared papers, 2024–2026 · strength 1.24
  12. Izaak Quintus Molenaar · 7 shared papers, 2024–2026 · strength 1.24
  13. Joseph R. Habib · 7 shared papers, 2024–2026 · strength 1.24
  14. Marionna Cathomas · 3 shared papers, 2026 · strength 1.16
  15. Paul C. M. Andel · 6 shared papers, 2024–2026 · strength 1.11
  16. Rosa Klotz · 4 shared papers, 2024–2026 · strength 0.96
  17. Greg D. Sacks · 5 shared papers, 2024–2026 · strength 0.95
  18. Brady A. Campbell · 5 shared papers, 2024–2026 · strength 0.94
  19. Miriam Klauß · 4 shared papers, 2021–2026 · strength 0.83
  20. Philipp Mayer · 4 shared papers, 2021–2026 · strength 0.83
  21. Christopher L. Wolfgang · 5 shared papers, 2024–2025 · strength 0.83
  22. Jing He · 4 shared papers, 2024–2026 · strength 0.76
  23. Adrian Theophil Billeter · 4 shared papers, 2024–2026 · strength 0.76
  24. Jörg Kaiser · 4 shared papers, 2024–2025 · strength 0.72
  25. Daniel Brock Hewitt · 4 shared papers, 2024–2025 · strength 0.71

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.